Cargando…
CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (L...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882723/ https://www.ncbi.nlm.nih.gov/pubmed/33597968 http://dx.doi.org/10.3389/fgene.2020.600227 |
_version_ | 1783651105352187904 |
---|---|
author | Liu, Wei Yi, Jin-Mou Liu, Yi Chen, Cong Zhang, Kai-Xuan Zhou, Cheng Zhan, Hui-En Zhao, Liang Morales, Stephanie Zhao, Xie-Lan Zeng, Hui |
author_facet | Liu, Wei Yi, Jin-Mou Liu, Yi Chen, Cong Zhang, Kai-Xuan Zhou, Cheng Zhan, Hui-En Zhao, Liang Morales, Stephanie Zhao, Xie-Lan Zeng, Hui |
author_sort | Liu, Wei |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (LSC), has the potential to predict the prognosis of AML. By analyzing public databases, we observed that the messenger RNA (mRNA) levels of CDK6 were significantly overexpressed in AML cell lines and non-acute promyelocytic leukemia (non-APL) AML patients when compared to healthy donors. Furthermore, CDK6 expression was significantly reduced in AML patients who achieved complete remission (CR) compared to that at the time of diagnosis in our validated cohort. The expression of CDK6 was tightly correlated with peripheral blood blasts, French–American–British (FAB) subtypes, CCAAT-enhancer-binding protein α (CEBPA) mutation, and chromosomal abnormalities of t(8;21). However, the clinical significance and effects of CDK6 expression on the prognosis of non-APL AML patients remain uncertain. We found that CDK6 expression was inversely correlated with overall survival (OS) among non-APL AML patients using the Kaplan–Meier analysis. CDK6 was also found to be positively associated with genes identified to contribute to the development of leukemia, including CCND2, DNMT3B, SOX4, and IKZF2, as well as being negatively associated with anticancer microRNAs, including miR-187, miR-9, miR-582, miR708, and miR-362. In summary, our study revealed that CDK6 might be a potential diagnostic and prognostic biomarker in non-APL AML patients. |
format | Online Article Text |
id | pubmed-7882723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78827232021-02-16 CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia Liu, Wei Yi, Jin-Mou Liu, Yi Chen, Cong Zhang, Kai-Xuan Zhou, Cheng Zhan, Hui-En Zhao, Liang Morales, Stephanie Zhao, Xie-Lan Zeng, Hui Front Genet Genetics Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (LSC), has the potential to predict the prognosis of AML. By analyzing public databases, we observed that the messenger RNA (mRNA) levels of CDK6 were significantly overexpressed in AML cell lines and non-acute promyelocytic leukemia (non-APL) AML patients when compared to healthy donors. Furthermore, CDK6 expression was significantly reduced in AML patients who achieved complete remission (CR) compared to that at the time of diagnosis in our validated cohort. The expression of CDK6 was tightly correlated with peripheral blood blasts, French–American–British (FAB) subtypes, CCAAT-enhancer-binding protein α (CEBPA) mutation, and chromosomal abnormalities of t(8;21). However, the clinical significance and effects of CDK6 expression on the prognosis of non-APL AML patients remain uncertain. We found that CDK6 expression was inversely correlated with overall survival (OS) among non-APL AML patients using the Kaplan–Meier analysis. CDK6 was also found to be positively associated with genes identified to contribute to the development of leukemia, including CCND2, DNMT3B, SOX4, and IKZF2, as well as being negatively associated with anticancer microRNAs, including miR-187, miR-9, miR-582, miR708, and miR-362. In summary, our study revealed that CDK6 might be a potential diagnostic and prognostic biomarker in non-APL AML patients. Frontiers Media S.A. 2021-02-01 /pmc/articles/PMC7882723/ /pubmed/33597968 http://dx.doi.org/10.3389/fgene.2020.600227 Text en Copyright © 2021 Liu, Yi, Liu, Chen, Zhang, Zhou, Zhan, Zhao, Morales, Zhao and Zeng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Liu, Wei Yi, Jin-Mou Liu, Yi Chen, Cong Zhang, Kai-Xuan Zhou, Cheng Zhan, Hui-En Zhao, Liang Morales, Stephanie Zhao, Xie-Lan Zeng, Hui CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia |
title | CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia |
title_full | CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia |
title_fullStr | CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia |
title_full_unstemmed | CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia |
title_short | CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia |
title_sort | cdk6 is a potential prognostic biomarker in acute myeloid leukemia |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882723/ https://www.ncbi.nlm.nih.gov/pubmed/33597968 http://dx.doi.org/10.3389/fgene.2020.600227 |
work_keys_str_mv | AT liuwei cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT yijinmou cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT liuyi cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT chencong cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT zhangkaixuan cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT zhoucheng cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT zhanhuien cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT zhaoliang cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT moralesstephanie cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT zhaoxielan cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia AT zenghui cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia |